Earnings ·
Eton Pharmaceuticals reported second quarter 2026 financial results on August 13, 2026
ETONEton Pharmaceuticals, Inc.
Eton Pharmaceuticals reported second quarter 2026 financial results on August 13, 2026. The company achieved record revenue of $37.6 million, a 99% increase from the prior year period, driven by HEMANGEOL sales and growth across its portfolio. GAAP net income was $11.6 million ($0.35 per diluted share), compared to a net loss in the previous year. The company raised its full-year revenue guidance to exceed $145 million, up from over $120 million, and increased Adjusted EBITDA margin guidance to at least 35%. Key operational highlights include the successful relaunch of HEMANGEOL with 95% patient conversion, the licensing of late-stage candidate ASN-001 for a potential 2027 NDA submission, FDA Fast Track designation for AMGLIDIA, and the acquisition of U.S. commercialization rights to IMPAVIDO. Eton Pharmaceuticals is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases.